CRP predicted prognosis in 23 of 24 (96%) studies in pancreatic cancer [68–71], 22 of 24 (92%) in lung cancer [25, 72–74], all 10 in hepatocellular carcinoma (HCC) [75–77], all 5 in melanoma [23, 78], 4 of 7 (57%) in breast cancer [79, 80], 12 of 12 (100%) in bladder cancer [81–83], 7 of 9 (78%) in prostate cancer [84–86] and 21 of 24 (88%) others (cervical cancer, ovarian cancer, bone and soft tissue etc.)[87–91]. Here, CRP is linked to ovarian cancer.